A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

NCT01400503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Multicentric Castleman's Disease

Interventions

DRUG: Siltuximab

Sponsor

Janssen Research & Development, LLC